<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:21f96b13-7268-499f-97d2-8a1cdd09477c,g:f52a7ef9-1abc-422f-8315-42d1a370e695,d:afcbeb784ea54956b52acad41fdaaeae--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrtx-20220709</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xOS9mcmFnOjE1YzZkNzg4MzQwNTRhZTA5YTY2YTdkNWY3NjczNjllL3RhYmxlOmNiM2JjNDM4MmQ0MDQ1YzZiYzMxZTdlN2JkMjkyNjQ4L3RhYmxlcmFuZ2U6Y2IzYmM0MzgyZDQwNDVjNmJjMzFlN2U3YmQyOTI2NDhfMi0xLTEtMS0xMDgxMjU_4ce59883-be27-4da9-9224-e75d4fbe0ce8">0000875320</ix:nonNumeric><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xOS9mcmFnOjE1YzZkNzg4MzQwNTRhZTA5YTY2YTdkNWY3NjczNjllL3RhYmxlOmNiM2JjNDM4MmQ0MDQ1YzZiYzMxZTdlN2JkMjkyNjQ4L3RhYmxlcmFuZ2U6Y2IzYmM0MzgyZDQwNDVjNmJjMzFlN2U3YmQyOTI2NDhfMy0xLTEtMS0xMDgxMjU_721a195b-1f96-4287-924c-4f3a988efa57">VERTEX PHARMACEUTICALS INC / MA</ix:nonNumeric><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xOS9mcmFnOjE1YzZkNzg4MzQwNTRhZTA5YTY2YTdkNWY3NjczNjllL3RhYmxlOmNiM2JjNDM4MmQ0MDQ1YzZiYzMxZTdlN2JkMjkyNjQ4L3RhYmxlcmFuZ2U6Y2IzYmM0MzgyZDQwNDVjNmJjMzFlN2U3YmQyOTI2NDhfNi0xLTEtMS0xMDgxMjU_c4d1708e-61ec-4b0a-b4d6-6b837dd30d23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrtx-20220709.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-09</xbrli:startDate><xbrli:endDate>2022-07-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iafcbeb784ea54956b52acad41fdaaeae_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:232%">FORM <ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjEz_e2b9f3f8-dc8e-49b8-9238-68bf65db72a6">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8yMjQ_24c28150-0ca9-4167-b54c-8a9031d635dc">July 9, 2022</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:144%">Vertex Pharmaceuticals Incorporated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGFibGU6N2E5NzM1MjFjMDU4NGU0Zjk2MDY0MWM1NjFkNDFhN2EvdGFibGVyYW5nZTo3YTk3MzUyMWMwNTg0ZTRmOTYwNjQxYzU2MWQ0MWE3YV8wLTAtMS0xLTEwODEyNQ_2f329200-d82a-4b04-ad95-333ad06045d0">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGFibGU6N2E5NzM1MjFjMDU4NGU0Zjk2MDY0MWM1NjFkNDFhN2EvdGFibGVyYW5nZTo3YTk3MzUyMWMwNTg0ZTRmOTYwNjQxYzU2MWQ0MWE3YV8wLTEtMS0xLTEwODEyNQ_86d9a198-96d3-4f00-a9f2-9193a931ed6f">000-19319</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGFibGU6N2E5NzM1MjFjMDU4NGU0Zjk2MDY0MWM1NjFkNDFhN2EvdGFibGVyYW5nZTo3YTk3MzUyMWMwNTg0ZTRmOTYwNjQxYzU2MWQ0MWE3YV8wLTItMS0xLTEwODEyNQ_fae6a011-66fc-4ff4-9d6b-97cc090d4046">04-3039129</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjE0_349a1235-4f49-45d8-bcaf-30e42ae8e8fa">50 Northern Avenue</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjE1_4af528f2-270e-4bb8-b1b4-1f7fe5bc6001">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjIw_dfef13bf-64d0-4a5c-b7ae-bd092cdfc335">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjIx_9491a646-a005-483e-92fe-1b92e33be568">02210</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:144%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjE2_05edec37-f31a-4f50-8187-e515901422eb">617</ix:nonNumeric>) <ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjIy_bb9d0813-6a56-4f44-b485-a04f3550dbab">341-6100</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjIz_96812015-e99b-45cb-9756-458a03cc6617">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjI0_2a06aa08-1317-470c-a842-9a7a3ca9150a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjE3_8874314b-e99c-47b2-a192-b2258125e2d1">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjE4_bc226f50-81a0-4226-8148-d8f5471b6be5">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGFibGU6NjMyOTFkZjk4NzE5NDY2OWEyZTllZDNjZDkyOGVkNDcvdGFibGVyYW5nZTo2MzI5MWRmOTg3MTk0NjY5YTJlOWVkM2NkOTI4ZWQ0N18yLTAtMS0xLTEwODEyNQ_60b916ef-d57c-4d90-8eb6-7d2343dc54f5">Common Stock, $0.01 Par Value Per Share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGFibGU6NjMyOTFkZjk4NzE5NDY2OWEyZTllZDNjZDkyOGVkNDcvdGFibGVyYW5nZTo2MzI5MWRmOTg3MTk0NjY5YTJlOWVkM2NkOTI4ZWQ0N18yLTItMS0xLTEwODEyNQ_97fe22cc-df2e-41de-bc2c-27dccde5806c">VRTX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGFibGU6NjMyOTFkZjk4NzE5NDY2OWEyZTllZDNjZDkyOGVkNDcvdGFibGVyYW5nZTo2MzI5MWRmOTg3MTk0NjY5YTJlOWVkM2NkOTI4ZWQ0N18yLTQtMS0xLTEwODEyNQ_8875ba79-2e79-4dd3-a2d6-7e78638c94d3">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id8fb19ad949b41fe88129e995ad15cd1_D20220709-20220709" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFmY2JlYjc4NGVhNTQ5NTZiNTJhY2FkNDFmZGFhZWFlL3NlYzphZmNiZWI3ODRlYTU0OTU2YjUyYWNhZDQxZmRhYWVhZV8xL2ZyYWc6M2Y3OGVlYjI3OWNiNDdjYWFjYTk0MjBjYzlhODJjY2IvdGV4dHJlZ2lvbjozZjc4ZWViMjc5Y2I0N2NhYWNhOTQyMGNjOWE4MmNjYl8xNjE5_bee9b213-0bca-4c45-a3b4-3c7b1db65458">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iafcbeb784ea54956b52acad41fdaaeae_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 8.01 Other Events.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 9, 2022, Vertex Pharmaceuticals Incorporated (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Vertex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) entered into an Agreement and Plan of Merger (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with ViaCyte, Inc. (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ViaCyte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Vanilla Merger Sub, Inc., a wholly-owned subsidiary of Vertex (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Sub</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Shareholder Representative Services LLC, solely in its capacity as equityholders&#8217; representative thereunder. The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into ViaCyte (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Merger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), with ViaCyte surviving the Merger as a wholly-owned subsidiary of Vertex. ViaCyte is </span><span style="color:#1b252b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the terms of the Merger Agreement, Vertex has agreed to a payment of approximately $320 million in cash upon consummation of the Merger. A portion of this consideration will be escrowed to satisfy customary post-closing indemnification obligations of ViaCyte equityholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Merger Agreement and the Merger have been approved by the board of directors of ViaCyte. The completion of the Merger is subject to certain customary conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended and the absence of any material adverse effect with respect to ViaCyte. Vertex intends to fund the acquisition using cash on hand or other sources of immediately available funds. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following the execution of the Merger Agreement, stockholders of ViaCyte sufficient to approve the Merger delivered irrevocable written consents approving and authorizing the Merger and adopting the Merger Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 11, 2022, Vertex issued a press release announcing the execution of the Merger Agreement. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, information regarding how Vertex plans to fund the acquisition. While Vertex believes the forward-looking statements contained in this report are accurate, these forward-looking statements represent the company&#8217;s beliefs only as of the date of this report, and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the transaction is subject to certain conditions, including the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act, that Vertex may not realize the potential benefits of the transaction, that data from a limited number of patients may not be indicative of final clinical trial results, and that data from the company&#8217;s development programs, including the T1D programs, may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, or other reasons, and other risks listed under the heading &#8220;Risk Factors&#8221; in Vertex&#8217;s annual report filed with the Securities and Exchange Commission and available through the company&#8217;s website at www.vrtx.com and on the SEC&#8217;s website at www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this report as new information becomes available.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iafcbeb784ea54956b52acad41fdaaeae_188"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Item 9.01 Financial Statements and Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">&#160;&#160;&#160;&#160;(d)  Exhibits</span></div><div style="margin-bottom:9pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.064%"><tr><td style="width:1.0%"></td><td style="width:8.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex991_pressreleasejuly1120.htm">Press Release issued by Vertex, dated July 11, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File &#8212; the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iafcbeb784ea54956b52acad41fdaaeae_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#160; </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VERTEX PHARMACEUTICALS INCORPORATED</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:99pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date: July 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Joy Liu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Joy Liu</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Senior Vice President and General Counsel</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "vrtx-20220709.htm", "description": "8-K", "secsgml_size_bytes": 38074}]
{"company-data": {"conformed-name": "VERTEX PHARMACEUTICALS INC / MA", "cik": "0000875320", "assigned-sic": "2834", "irs-number": "043039129", "state-of-incorporation": "MA", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19319", "film-number": "221075907"}, "business-address": {"street1": "50 NORTHERN AVENUE", "city": "BOSTON", "state": "MA", "zip": "02210", "phone": "6173416393"}, "mail-address": {"street1": "50 NORTHERN AVENUE", "city": "BOSTON", "state": "MA", "zip": "02210"}}
vrtx-20220709
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July 9, 2022
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
000-19319
04-3039129
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
50 Northern Avenue
Boston
,
Massachusetts
02210
(Address of principal executive offices) (Zip Code)
(
617
)
341-6100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On July 9, 2022, Vertex Pharmaceuticals Incorporated ("
Vertex
") entered into an Agreement and Plan of Merger (the "
Merger Agreement
") with ViaCyte, Inc. ("
ViaCyte
"), Vanilla Merger Sub, Inc., a wholly-owned subsidiary of Vertex ("
Merger Sub
"), and Shareholder Representative Services LLC, solely in its capacity as equityholders' representative thereunder. The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into ViaCyte (the "
Merger
"), with ViaCyte surviving the Merger as a wholly-owned subsidiary of Vertex. ViaCyte is
a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D).
Under the terms of the Merger Agreement, Vertex has agreed to a payment of approximately $320 million in cash upon consummation of the Merger. A portion of this consideration will be escrowed to satisfy customary post-closing indemnification obligations of ViaCyte equityholders.
The Merger Agreement and the Merger have been approved by the board of directors of ViaCyte. The completion of the Merger is subject to certain customary conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended and the absence of any material adverse effect with respect to ViaCyte. Vertex intends to fund the acquisition using cash on hand or other sources of immediately available funds.
Following the execution of the Merger Agreement, stockholders of ViaCyte sufficient to approve the Merger delivered irrevocable written consents approving and authorizing the Merger and adopting the Merger Agreement.
On July 11, 2022, Vertex issued a press release announcing the execution of the Merger Agreement. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Forward-Looking Statements.
This report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, information regarding how Vertex plans to fund the acquisition. While Vertex believes the forward-looking statements contained in this report are accurate, these forward-looking statements represent the company's beliefs only as of the date of this report, and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the transaction is subject to certain conditions, including the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act, that Vertex may not realize the potential benefits of the transaction, that data from a limited number of patients may not be indicative of final clinical trial results, and that data from the company's development programs, including the T1D programs, may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, or other reasons, and other risks listed under the heading "Risk Factors" in Vertex's annual report filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com and on the SEC's website at www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this report as new information becomes available.
Item 9.01 Financial Statements and Exhibits.
(d)  Exhibits
Exhibit
Description of Document
99.1
Press Release issued by Vertex, dated July 11, 2022.
104
Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: July 11, 2022
/s/ Joy Liu
Joy Liu
Senior Vice President and General Counsel